Defendant
2 cases as defendant.
Miracor Medical SA Belgium is a privately held European medical device company headquartered in Awans, Belgium. Founded in 2008, the company focuses on developing innovative therapies for patients with impaired cardiac function, particularly those who have experienced acute myocardial infarction (AMI). As of February 2026, Miracor Medical has approximately 7 employees. The company has raised a total of $117 million in funding across eight rounds.
Miracor Medical's primary product is the CE-marked PiCSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System. This system, consisting of a driving console and associated catheters, is designed to be used during primary percutaneous coronary intervention (PCI) in severe heart attack patients. The PiCSO Impulse System aims to improve outcomes by increasing blood flow to affected heart tissue, reducing infarct size, and enhancing overall heart function. The company has also received "Breakthrough Device Designation" from the FDA for its PiCSO Impulse System.
Miracor Medical SA Belgium has appeared as a defendant in one tracked case, ABBOTT LABORATORIES et al. v. Miracor Medical SA Belgium, before the Patent Trial and Appeal Board (PTAB) in 2025. This indicates an operating company defending against a patent challenge rather than asserting its own portfolio.
The company's core technology revolves around transvenous coronary sinus balloon catheter systems and pressure-controlled intermittent coronary sinus occlusion. As of April 2026, Miracor Medical is conducting post-market clinical trials of the PiCSO Impulse System in Europe and the US, including the randomized PiCSO-AMI-I trial in Europe and the FDA IDE-approved PiCSO-AMI-II trial in the US for anterior STEMI patients.
This is an Inter Partes Review (IPR) initiated by ABBOTT LABORATORIES and THORATEC LLC against the patent owner, Miracor Medical SA Belgium, concerning patent 11351357, which has been instituted at the Patent Trial and Appeal Board.
An Inter Partes Review (IPR) proceeding initiated by Abbott Laboratories and Thoratec LLC against patent owner Miracor Medical SA Belgium challenging US patent 11351356.